Pub Date : 2015-09-01DOI: 10.4103/2356-8062.178289
S. Assaad, M. Sobhy, T. Elsherbiny, R. Swelem, M. Allam
Background Thyroid hormonal disturbance plays an essential role in coronary artery disease (CAD) development and progress. Few studies have detected the relation between percutaneous coronary intervention (PCI), thyroid gland function, and morphology. We aimed to assess the influence of baseline thyroid function tests on the outcome of PCI in euthyroid patients with CAD, and to detect the effect of PCI on the thyroid function and ultrasound features. Patients and methods This study included 113 clinically euthyroid patients with stable CAD. Serum free T3, serum free T4, thyroid-stimulating hormone (TSH), thyroid-stimulating hormone index, free T3/T4 ratio, anti-thyroperoxidase (TPO), and high-sensitivity C-reactive protein had been measured before, and then 24 h and 3 months after PCI. The morphology of thyroid was evaluated through thyroid ultrasound before and 3 months after PCI. Results One day after PCI, there was a significant increase in serum FT3 and serum FT4 and no significant change in the serum TSH compared with just before PCI (P < 0.001, P = 0.04, P = 0.97, respectively). In addition, there was a significant increase in serum FT3/FT4 ratio compared with just before PCI (P = 0.007). Three months after PCI, there was a significant increase in serum FT4, decrease in serum FT3 returning to baseline, and a significant increase in serum TSH compared with just before PCI (P = 0.42, P < 0.001, P < 0.001, respectively). There was a significant decrease in the serum FT3/FT4 ratio and significant increase in serum thyroid-stimulating hormone index compared with just before PCI ( P ≤ 0.001, P < 0.001, respectively). Higher TSH and measured echogenicity index were independent pre-PCI predictors of unfavorable outcomes after 24 h with cutoff values greater than 0.95 mIU/ml and greater than 1.81, respectively. Lower FT3 and higher FT4 levels were independent pre-PCI predictors of unfavorable outcomes after 3 months with cutoff values less than or equal to 2.95 pg/ml and greater than 1.3 ng/dl, respectively. Conclusion A state of euthyroid hyperthyroxinemia was detected 24 h after PCI. A state of thyroid hormone resistance was detected 3 months after PCI. Higher TSH and measured echogenicity index independently predicted unfavorable outcome after 24 h. Lower FT3 and higher FT4 levels independently predicted unfavorable outcomes after 3 months.
背景甲状腺激素紊乱在冠状动脉疾病(CAD)的发生发展中起重要作用。很少有研究发现经皮冠状动脉介入治疗(PCI)与甲状腺功能和形态学之间的关系。我们的目的是评估基线甲状腺功能检查对冠心病甲状腺功能正常患者PCI治疗结果的影响,并检测PCI对甲状腺功能和超声特征的影响。患者与方法本研究纳入113例临床甲状腺功能正常的稳定型冠心病患者。术前、术后24 h、3个月分别测定血清游离T3、游离T4、促甲状腺激素(TSH)、促甲状腺激素指数、游离T3/T4比值、抗甲状腺过氧化物酶(TPO)、高敏c反应蛋白。术前和术后3个月分别行甲状腺超声检查。结果PCI术后1 d血清FT3、FT4较PCI前明显升高,血清TSH无明显变化(P < 0.001, P = 0.04, P = 0.97)。此外,与PCI前相比,血清FT3/FT4比值显著升高(P = 0.007)。PCI术后3个月,与PCI前比较,血清FT4显著升高,血清FT3降低至基线水平,血清TSH显著升高(P = 0.42, P < 0.001, P < 0.001)。与PCI前比较,血清FT3/FT4比值显著降低,血清促甲状腺激素指数显著升高(P≤0.001,P < 0.001)。较高的TSH和回声指数是24 h后不良预后的独立pci前预测指标,临界值分别大于0.95 mIU/ml和大于1.81。较低的FT3和较高的FT4水平是3个月后不良结局的独立pci前预测指标,临界值分别小于或等于2.95 pg/ml和大于1.3 ng/dl。结论PCI术后24 h可检出甲亢血症。PCI术后3个月检测甲状腺激素抵抗状态。较高的TSH和测量的回声指数独立预测24小时后的不良结果。较低的FT3和较高的FT4水平独立预测3个月后的不良结果。
{"title":"Influence of thyroid function on the outcome of percutaneous coronary intervention in euthyroid patients with coronary artery disease","authors":"S. Assaad, M. Sobhy, T. Elsherbiny, R. Swelem, M. Allam","doi":"10.4103/2356-8062.178289","DOIUrl":"https://doi.org/10.4103/2356-8062.178289","url":null,"abstract":"Background Thyroid hormonal disturbance plays an essential role in coronary artery disease (CAD) development and progress. Few studies have detected the relation between percutaneous coronary intervention (PCI), thyroid gland function, and morphology. We aimed to assess the influence of baseline thyroid function tests on the outcome of PCI in euthyroid patients with CAD, and to detect the effect of PCI on the thyroid function and ultrasound features. Patients and methods This study included 113 clinically euthyroid patients with stable CAD. Serum free T3, serum free T4, thyroid-stimulating hormone (TSH), thyroid-stimulating hormone index, free T3/T4 ratio, anti-thyroperoxidase (TPO), and high-sensitivity C-reactive protein had been measured before, and then 24 h and 3 months after PCI. The morphology of thyroid was evaluated through thyroid ultrasound before and 3 months after PCI. Results One day after PCI, there was a significant increase in serum FT3 and serum FT4 and no significant change in the serum TSH compared with just before PCI (P < 0.001, P = 0.04, P = 0.97, respectively). In addition, there was a significant increase in serum FT3/FT4 ratio compared with just before PCI (P = 0.007). Three months after PCI, there was a significant increase in serum FT4, decrease in serum FT3 returning to baseline, and a significant increase in serum TSH compared with just before PCI (P = 0.42, P < 0.001, P < 0.001, respectively). There was a significant decrease in the serum FT3/FT4 ratio and significant increase in serum thyroid-stimulating hormone index compared with just before PCI ( P ≤ 0.001, P < 0.001, respectively). Higher TSH and measured echogenicity index were independent pre-PCI predictors of unfavorable outcomes after 24 h with cutoff values greater than 0.95 mIU/ml and greater than 1.81, respectively. Lower FT3 and higher FT4 levels were independent pre-PCI predictors of unfavorable outcomes after 3 months with cutoff values less than or equal to 2.95 pg/ml and greater than 1.3 ng/dl, respectively. Conclusion A state of euthyroid hyperthyroxinemia was detected 24 h after PCI. A state of thyroid hormone resistance was detected 3 months after PCI. Higher TSH and measured echogenicity index independently predicted unfavorable outcome after 24 h. Lower FT3 and higher FT4 levels independently predicted unfavorable outcomes after 3 months.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"107 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115834517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-01DOI: 10.4103/2356-8062.178345
Nany Hasan El Gayar, A. Deghady
Objective The aim of this study was to examine the status of iron and the significance of soluble transferrin receptors (sTfR) in healthy elderly population. Participants and methods This study was carried out on 30 healthy elderly individuals (15 men and 15 women) above 65 years of age (the elderly group); in addition, 10 young participants served as controls (the control group). Serum iron level, total capacity of iron binding (TIBC), ferritin, and hemoglobin were measured. The level of sTfR was measured with a commercial kit using BioVendor Humans sTfR ELISA. Results Significant statistical decrease in hemoglobin level (P = 0.0007), ferritin (P = 0.00001), and serum iron (P = 0.00001), and a significant statistical increase in sTfR (P = 0.0013) were found in the elderly group. There was no statistical significant difference in TIBC (P = 0.4719) and significant negative correlation between sTfR and ferritin, TIBC, hemoglobin, and serum iron. Conclusion Serum iron decreases with advancing age and sTfR level increases. sTfR is negatively correlated with serum iron level and can be used as a reliable marker for iron stores, as sTfR is not affected by acute inflammatory conditions. sTfR measurement is useful in the diagnosis of iron deficiency.
{"title":"Iron status in healthy elderly people: an evaluation of the role of soluble transferrin receptors in elderly","authors":"Nany Hasan El Gayar, A. Deghady","doi":"10.4103/2356-8062.178345","DOIUrl":"https://doi.org/10.4103/2356-8062.178345","url":null,"abstract":"Objective The aim of this study was to examine the status of iron and the significance of soluble transferrin receptors (sTfR) in healthy elderly population. Participants and methods This study was carried out on 30 healthy elderly individuals (15 men and 15 women) above 65 years of age (the elderly group); in addition, 10 young participants served as controls (the control group). Serum iron level, total capacity of iron binding (TIBC), ferritin, and hemoglobin were measured. The level of sTfR was measured with a commercial kit using BioVendor Humans sTfR ELISA. Results Significant statistical decrease in hemoglobin level (P = 0.0007), ferritin (P = 0.00001), and serum iron (P = 0.00001), and a significant statistical increase in sTfR (P = 0.0013) were found in the elderly group. There was no statistical significant difference in TIBC (P = 0.4719) and significant negative correlation between sTfR and ferritin, TIBC, hemoglobin, and serum iron. Conclusion Serum iron decreases with advancing age and sTfR level increases. sTfR is negatively correlated with serum iron level and can be used as a reliable marker for iron stores, as sTfR is not affected by acute inflammatory conditions. sTfR measurement is useful in the diagnosis of iron deficiency.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125050596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-01DOI: 10.4103/2356-8062.178320
M. Saad, M. Mahmood
Background Frailty is an age-associated syndrome characterized by a reduced functional reserve and impaired adaptive capacity. Age-ass ociated decline in sex-hormone levels represent one of the potential mechanisms involved in the development of frailty. We aimed at studying the association of serum testosterone and serum estradiol levels with frailty in elderly Egyptian men and women, and evaluating sex-specific differences in the association between testosterone and estradiol levels with frailty. Materials and methods A total of 94 elderly participants (55 men and 39 women), aged 65 years and older, were included in the present study. Participants were divided into three groups according to their frailty status, which was determined according to the Fried criteria. Total testosterone (TT), free testosterone (FT), and total estradiol (E2) were determined. Results For men, frailty was significantly correlated with TT and FT but not with E2, whereas, for women, frailty was significantly correlated with FT and E2 but not with TT. In addition, BMI was significantly correlated with frailty for both men and women. Conclusion We concluded that lower levels of FT are associated with frailty for both men and women, whereas lower levels of TT are associated with frailty in men but not in women. Estradiol (E2) is correlated with frailty in women but not in men. In light of these findings, men with low levels of testosterone are at an increased risk for physical frailty and could thus benefit from testosterone therapy. In addition, postmenopausal women might also benefit from testosterone administration and estrogen supplementation in the context of a wider hormonal care.
{"title":"Evaluation of sex-specific association of serum testosterone and estradiol levels with frailty in elderly Egyptian men and women","authors":"M. Saad, M. Mahmood","doi":"10.4103/2356-8062.178320","DOIUrl":"https://doi.org/10.4103/2356-8062.178320","url":null,"abstract":"Background Frailty is an age-associated syndrome characterized by a reduced functional reserve and impaired adaptive capacity. Age-ass ociated decline in sex-hormone levels represent one of the potential mechanisms involved in the development of frailty. We aimed at studying the association of serum testosterone and serum estradiol levels with frailty in elderly Egyptian men and women, and evaluating sex-specific differences in the association between testosterone and estradiol levels with frailty. Materials and methods A total of 94 elderly participants (55 men and 39 women), aged 65 years and older, were included in the present study. Participants were divided into three groups according to their frailty status, which was determined according to the Fried criteria. Total testosterone (TT), free testosterone (FT), and total estradiol (E2) were determined. Results For men, frailty was significantly correlated with TT and FT but not with E2, whereas, for women, frailty was significantly correlated with FT and E2 but not with TT. In addition, BMI was significantly correlated with frailty for both men and women. Conclusion We concluded that lower levels of FT are associated with frailty for both men and women, whereas lower levels of TT are associated with frailty in men but not in women. Estradiol (E2) is correlated with frailty in women but not in men. In light of these findings, men with low levels of testosterone are at an increased risk for physical frailty and could thus benefit from testosterone therapy. In addition, postmenopausal women might also benefit from testosterone administration and estrogen supplementation in the context of a wider hormonal care.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123056611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-01DOI: 10.4103/2356-8062.178291
M. Saad, Samar Abd El-Fattah, Mohamed Gad, A. Deghady
Introduction Frailty is a common and growing multidimensional health and social care challenge across the world. Diabetes mellitus (DM) is one of the most important causes of morbidity and mortality in Egypt. Frailty and diabetes are inter-related. In addition, diabetes causes early-onset frailty. In this study we aimed to determine the frailty index in elderly men with type 2 DM and compare it with that in pre-elderly diabetic patients and age-matched healthy controls. Materials and methods Seventy male participants were included in the present study and were divided into three groups. Group I comprised 20 healthy men aged 65-75 years who were considered the control group; group II comprised 25 patients aged 50-64 years with type 2 DM; and group III comprised 25 patients aged 65-75 years with type 2 DM. Patients on insulin therapy and those with hypogonadism or hypothyroidism were excluded from the study. Frailty index was determined for all participants using Fried′s five phenotypic parameters. Patients were considered frail if they fulfilled more than or equal to three parameters, prefrail if they fulfilled one to two parameters, and nonfrail if they fulfilled none of the parameters. Data were collected, analyzed, and compared between groups I and III and between groups II and III. Further, frailty index was correlated with the duration of DM and the degree of glycemic control. Results Seventy patients were divided into three groups. The mean age in group I was 68.50 ± 1.90 years, that in group II was 58.24 ± 4.34 years, and that in group III was 68.60 ± 2.43 years. Regarding the frailty index, in group I 17 patients (85%) were nonfrail, three (15%) were prefrail, and none were frail; in group II, four patients (16%) were prefrail, 21 (84%) were frail, and none were nonfrail; and in group III, three patients (12%) were prefrail, 22 (88%) were frail, and none were nonfrail. A statistically significant difference was noted between groups I and III, whereas no significant difference was noted between groups II and III. A significant positive correlation was found between the frailty index score and duration of diabetes and degree of glycemic control in groups II and III. Conclusion Diabetes and frailty are causally related. Diabetes is associated with frailty at earlier age. The duration of diabetes and degree of glycemic control correlate with the severity of frailty in both elderly and pre-elderly diabetic patients.
{"title":"Study of frailty index in elderly men with type 2 diabetes mellitus","authors":"M. Saad, Samar Abd El-Fattah, Mohamed Gad, A. Deghady","doi":"10.4103/2356-8062.178291","DOIUrl":"https://doi.org/10.4103/2356-8062.178291","url":null,"abstract":"Introduction Frailty is a common and growing multidimensional health and social care challenge across the world. Diabetes mellitus (DM) is one of the most important causes of morbidity and mortality in Egypt. Frailty and diabetes are inter-related. In addition, diabetes causes early-onset frailty. In this study we aimed to determine the frailty index in elderly men with type 2 DM and compare it with that in pre-elderly diabetic patients and age-matched healthy controls. Materials and methods Seventy male participants were included in the present study and were divided into three groups. Group I comprised 20 healthy men aged 65-75 years who were considered the control group; group II comprised 25 patients aged 50-64 years with type 2 DM; and group III comprised 25 patients aged 65-75 years with type 2 DM. Patients on insulin therapy and those with hypogonadism or hypothyroidism were excluded from the study. Frailty index was determined for all participants using Fried′s five phenotypic parameters. Patients were considered frail if they fulfilled more than or equal to three parameters, prefrail if they fulfilled one to two parameters, and nonfrail if they fulfilled none of the parameters. Data were collected, analyzed, and compared between groups I and III and between groups II and III. Further, frailty index was correlated with the duration of DM and the degree of glycemic control. Results Seventy patients were divided into three groups. The mean age in group I was 68.50 ± 1.90 years, that in group II was 58.24 ± 4.34 years, and that in group III was 68.60 ± 2.43 years. Regarding the frailty index, in group I 17 patients (85%) were nonfrail, three (15%) were prefrail, and none were frail; in group II, four patients (16%) were prefrail, 21 (84%) were frail, and none were nonfrail; and in group III, three patients (12%) were prefrail, 22 (88%) were frail, and none were nonfrail. A statistically significant difference was noted between groups I and III, whereas no significant difference was noted between groups II and III. A significant positive correlation was found between the frailty index score and duration of diabetes and degree of glycemic control in groups II and III. Conclusion Diabetes and frailty are causally related. Diabetes is associated with frailty at earlier age. The duration of diabetes and degree of glycemic control correlate with the severity of frailty in both elderly and pre-elderly diabetic patients.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"77 4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124451725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-01DOI: 10.4103/2356-8062.178324
Nany Hasan El Gayar, Marwa Mahmoud, A. Elabd
Objective The aim of the present study was to evaluate the relationship between serum testosterone concentration and carotid atherosclerosis in elderly men. Participants and methods The current study included 40 participants who were classified into two groups; the first group comprised 30 elderly healthy men (the case group) and the second group comprised 10 young males (the control group). Serum level of total testosterone was measured using a commercial immunoassay kit cobas testosterone II; sex hormone binding globulin (SHBG) was measured using a commercial immunoassay kit cobas. SHBG and free androgen index (FAI) were calculated by dividing the total testosterone value by SHBG value and then multiplying it by 100 [total testosterone (nmol/l)/SHBG (nmol/l)Χ100%]. Ultrasonographic measurement of carotid intima-media thickness (IMT) was also carried out. Results Total testosterone level was significantly lower in the case group than in the control group (t = 5.354, P < 0.001). SHBG was significantly higher in the case group than in the control group (t = 4.796, P < 0.001). FAI was significantly lower in the case group than in the control group (z = 4.686, P < 0.001). IMT was significantly higher in the case group than in the control group (t = 3.513, P = 0.001). As regards the number of plaques, 10 men participants (33.3%) from the case group did not have any plaques, 13 (43.3%) had one plaque, and seven (23.3%) had two plaques; however, in the control group, nine participants (90%) did not have any plaques and only one (10%) had one plaque; therefore, the case group had significantly higher number of plaques than did the control group (z = 3.007, P = 0.003). There was a significant negative correlation between total testosterone and SHBG (R = −0.856, P < 0.001), a significant positive correlation between total testosterone and FAI (R = 0.957, P < 0.001), and a significant negative correlation between testosterone and both IMT (R = −0.501, P = 0.005) and number of plaques (R = −0.358, P = 0.52). SHBG was negatively correlated with FAI (R = −0.845, P < 0.001) but positively correlated with both IMT (R = 0.392, P = 0353) and the number of plaques (R = 0.032, P = 0.056). There were significant negative correlations between FAI and both IMT (R = −0.601, P < 0.001) and the number of plaques (R = −0.461, P = 0.010). IMT was positively correlated with the number of plaques (R = 0.760, P < 0.001). Conclusion These findings suggest that normal physiologic testosterone levels may help to protect men from atherosclerosis. In elderly men, low plasma testosterone is associated with elevated carotid IMT. A negative correlation has been demonstrated between endogenous testosterone levels and IMT of the carotid arteries. These findings suggest that men with lower levels of endogenous testosterone may be at a higher risk for developing atherosclerosis.
目的探讨老年男性颈动脉粥样硬化与血清睾酮水平的关系。目前的研究包括40名参与者,他们被分为两组;第一组为30名健康老年男性(病例组),第二组为10名年轻男性(对照组)。使用商用免疫测定试剂盒cobas睾酮II测定血清总睾酮水平;性激素结合球蛋白(SHBG)使用商用免疫测定试剂盒cobas测定。总睾酮值除以SHBG值,再乘以100[总睾酮(nmol/l)/SHBG (nmol/l)Χ100%],计算SHBG和游离雄激素指数(FAI)。超声测量颈动脉内膜-中膜厚度(IMT)。结果病例组总睾酮水平显著低于对照组(t = 5.354, P < 0.001)。病例组SHBG明显高于对照组(t = 4.796, P < 0.001)。病例组FAI明显低于对照组(z = 4.686, P < 0.001)。病例组IMT显著高于对照组(t = 3.513, P = 0.001)。至于斑块的数量,病例组的10名男性参与者(33.3%)没有任何斑块,13名(43.3%)有一个斑块,7名(23.3%)有两个斑块;然而,在对照组中,9名参与者(90%)没有任何斑块,只有1名参与者(10%)有一个斑块;因此,病例组斑块数量明显高于对照组(z = 3.007, P = 0.003)。总睾酮与SHBG呈显著负相关(R = - 0.856, P < 0.001),总睾酮与FAI呈显著正相关(R = 0.957, P < 0.001),总睾酮与IMT (R = - 0.501, P = 0.005)和斑块数量呈显著负相关(R = - 0.358, P = 0.52)。SHBG与FAI呈负相关(R = - 0.845, P < 0.001),与IMT (R = 0.392, P = 0353)、斑块数量(R = 0.032, P = 0.056)呈正相关。FAI与IMT (R = - 0.601, P < 0.001)和斑块数量(R = - 0.461, P = 0.010)呈显著负相关。IMT与斑块数量呈正相关(R = 0.760, P < 0.001)。结论正常的生理性睾酮水平可能有助于预防动脉粥样硬化。老年男性血浆睾酮水平低与颈动脉IMT升高有关。内源性睾酮水平与颈动脉IMT呈负相关。这些发现表明,内源性睾酮水平较低的男性患动脉粥样硬化的风险更高。
{"title":"Study of the relation between serum testosterone level and carotid atherosclerosis in elderly men","authors":"Nany Hasan El Gayar, Marwa Mahmoud, A. Elabd","doi":"10.4103/2356-8062.178324","DOIUrl":"https://doi.org/10.4103/2356-8062.178324","url":null,"abstract":"Objective The aim of the present study was to evaluate the relationship between serum testosterone concentration and carotid atherosclerosis in elderly men. Participants and methods The current study included 40 participants who were classified into two groups; the first group comprised 30 elderly healthy men (the case group) and the second group comprised 10 young males (the control group). Serum level of total testosterone was measured using a commercial immunoassay kit cobas testosterone II; sex hormone binding globulin (SHBG) was measured using a commercial immunoassay kit cobas. SHBG and free androgen index (FAI) were calculated by dividing the total testosterone value by SHBG value and then multiplying it by 100 [total testosterone (nmol/l)/SHBG (nmol/l)Χ100%]. Ultrasonographic measurement of carotid intima-media thickness (IMT) was also carried out. Results Total testosterone level was significantly lower in the case group than in the control group (t = 5.354, P < 0.001). SHBG was significantly higher in the case group than in the control group (t = 4.796, P < 0.001). FAI was significantly lower in the case group than in the control group (z = 4.686, P < 0.001). IMT was significantly higher in the case group than in the control group (t = 3.513, P = 0.001). As regards the number of plaques, 10 men participants (33.3%) from the case group did not have any plaques, 13 (43.3%) had one plaque, and seven (23.3%) had two plaques; however, in the control group, nine participants (90%) did not have any plaques and only one (10%) had one plaque; therefore, the case group had significantly higher number of plaques than did the control group (z = 3.007, P = 0.003). There was a significant negative correlation between total testosterone and SHBG (R = −0.856, P < 0.001), a significant positive correlation between total testosterone and FAI (R = 0.957, P < 0.001), and a significant negative correlation between testosterone and both IMT (R = −0.501, P = 0.005) and number of plaques (R = −0.358, P = 0.52). SHBG was negatively correlated with FAI (R = −0.845, P < 0.001) but positively correlated with both IMT (R = 0.392, P = 0353) and the number of plaques (R = 0.032, P = 0.056). There were significant negative correlations between FAI and both IMT (R = −0.601, P < 0.001) and the number of plaques (R = −0.461, P = 0.010). IMT was positively correlated with the number of plaques (R = 0.760, P < 0.001). Conclusion These findings suggest that normal physiologic testosterone levels may help to protect men from atherosclerosis. In elderly men, low plasma testosterone is associated with elevated carotid IMT. A negative correlation has been demonstrated between endogenous testosterone levels and IMT of the carotid arteries. These findings suggest that men with lower levels of endogenous testosterone may be at a higher risk for developing atherosclerosis.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130692846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-05-01DOI: 10.4103/2356-8062.170204
A. Qasem, S. Farage, F. A. Elmesallamy, Hanaa H. Elsaid
Introduction The early prediction and prevention of cardiovascular disease risk factors is highly important in chronic kidney disease (CKD) patients. The plasma level of omentin was found to be associated with different disorders such as insulin resistance, diabetes mellitus, obesity, endothelial dysfunction, and atherosclerosis. The aim of the study was to clarify the influence of changes in levels of circulating omentin-1 on insulin resistance in CKD patients with and without type 2 diabetes mellitus. Participants and methods Seventy-eight patients were enrolled in this cross-sectional study: 23 patients with CKD on conservative treatment, 35 patients on maintenance hemodialysis, and 20 healthy volunteers. Serum concentrations of omentin-1 were determined with an enzyme-linked immunosorbent assay kit. Results Significant difference in plasma omentin-1 level was noticed between diabetic patients and nondiabetic patients in both the predialysis group and the hemodialysis (HD) group. There was also a significant difference in plasma omentin-1 level between nondiabetic patients in the predialysis group and the HD group and between diabetic patients in the predialysis group and hemodialysis group. There were significant negative correlation between plasma Omentin-1 level (ng/ml), fasting insulin level (mIU/ml), HOMA-IR and eGFR (ml/min/1.73m 2 ) while significant positive correlation with IL-6 (pg/ml) and hsCRP (mg/l). Conclusion Plasma omentin-1 concentration was higher in CKD patients. In addition, there was an association between omentin-1 and insulin resistance in hemodialysis patients, which may be considered a cardiovascular risk factor in CKD patients.
{"title":"Association of plasma omentin-1 level with insulin resistance in chronic kidney disease patients","authors":"A. Qasem, S. Farage, F. A. Elmesallamy, Hanaa H. Elsaid","doi":"10.4103/2356-8062.170204","DOIUrl":"https://doi.org/10.4103/2356-8062.170204","url":null,"abstract":"Introduction The early prediction and prevention of cardiovascular disease risk factors is highly important in chronic kidney disease (CKD) patients. The plasma level of omentin was found to be associated with different disorders such as insulin resistance, diabetes mellitus, obesity, endothelial dysfunction, and atherosclerosis. The aim of the study was to clarify the influence of changes in levels of circulating omentin-1 on insulin resistance in CKD patients with and without type 2 diabetes mellitus. Participants and methods Seventy-eight patients were enrolled in this cross-sectional study: 23 patients with CKD on conservative treatment, 35 patients on maintenance hemodialysis, and 20 healthy volunteers. Serum concentrations of omentin-1 were determined with an enzyme-linked immunosorbent assay kit. Results Significant difference in plasma omentin-1 level was noticed between diabetic patients and nondiabetic patients in both the predialysis group and the hemodialysis (HD) group. There was also a significant difference in plasma omentin-1 level between nondiabetic patients in the predialysis group and the HD group and between diabetic patients in the predialysis group and hemodialysis group. There were significant negative correlation between plasma Omentin-1 level (ng/ml), fasting insulin level (mIU/ml), HOMA-IR and eGFR (ml/min/1.73m 2 ) while significant positive correlation with IL-6 (pg/ml) and hsCRP (mg/l). Conclusion Plasma omentin-1 concentration was higher in CKD patients. In addition, there was an association between omentin-1 and insulin resistance in hemodialysis patients, which may be considered a cardiovascular risk factor in CKD patients.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131690823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-05-01DOI: 10.4103/2356-8062.170205
Manal A Mohsen, E. Algohary, S. Hassan, A. Elsherbeny, E. Abd El-hadi, A. El-Kholy
Introduction In humans, resistin antagonizes the effects of insulin on glucose metabolism in the liver and skeletal muscle, interacts with and reinforces inflammatory pathways, and may promote endothelial cell activation. Increased resistin levels have been associated with obesity, insulin resistance, metabolic syndrome, type 2 diabetes, and increased cardiovascular risk. Objectives Our study aimed to investigate the utility of maternal serum resistin in women with preeclampsia compared with normal pregnant women and its relation to insulin resistance. Patients and methods This study was carried out on 90 women who were divided into two groups: group I: preeclampsia (n = 60) and group II: healthy pregnant controls (n = 30). All individuals were subjected to the following after an informed oral and written consent was obtained: full assessment of history, clinical examination with a special focus on edema, blood pressure measurement, and maternal BMI [weight (kg)/height 2 (m 2 )]. Gestational age was determined according to the date of the last menstrual period and confirmed by first-trimester ultrasound. Laboratory investigations including complete blood count, aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, creatinine, homeostasis model assessment-insulin resistance (HOMA-IR), and serum resistin were performed. Results Statistical comparison between preeclamptic patients (group I) and the healthy control group (group II) in terms of the different parameters studied showed a highly statistically significant increase in the patient group compared with the control group in systolic blood pressure, diastolic blood pressure, BMI, creatinine (CRE), aspartate aminotransferase, alanine aminotransferase, 50 g oral glucose challenge test, fasting blood glucose, fasting insulin, HOMA-IR, and resistin. In contrast, there was a highly statistically significant decrease in the patient group than the control group in haemoglobin (HB). Conclusion In this study, it was found that elevated serum resistin levels could be associated with exaggerated insulin resistance in patients with preeclampsia. Further studies are needed to clarify the role of resistin in the pathophysiology of preeclampsia and insulin resistance.
{"title":"Study of possible relation between maternal serum resistin and insulin resistance in patients with preeclampsia","authors":"Manal A Mohsen, E. Algohary, S. Hassan, A. Elsherbeny, E. Abd El-hadi, A. El-Kholy","doi":"10.4103/2356-8062.170205","DOIUrl":"https://doi.org/10.4103/2356-8062.170205","url":null,"abstract":"Introduction In humans, resistin antagonizes the effects of insulin on glucose metabolism in the liver and skeletal muscle, interacts with and reinforces inflammatory pathways, and may promote endothelial cell activation. Increased resistin levels have been associated with obesity, insulin resistance, metabolic syndrome, type 2 diabetes, and increased cardiovascular risk. Objectives Our study aimed to investigate the utility of maternal serum resistin in women with preeclampsia compared with normal pregnant women and its relation to insulin resistance. Patients and methods This study was carried out on 90 women who were divided into two groups: group I: preeclampsia (n = 60) and group II: healthy pregnant controls (n = 30). All individuals were subjected to the following after an informed oral and written consent was obtained: full assessment of history, clinical examination with a special focus on edema, blood pressure measurement, and maternal BMI [weight (kg)/height 2 (m 2 )]. Gestational age was determined according to the date of the last menstrual period and confirmed by first-trimester ultrasound. Laboratory investigations including complete blood count, aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, creatinine, homeostasis model assessment-insulin resistance (HOMA-IR), and serum resistin were performed. Results Statistical comparison between preeclamptic patients (group I) and the healthy control group (group II) in terms of the different parameters studied showed a highly statistically significant increase in the patient group compared with the control group in systolic blood pressure, diastolic blood pressure, BMI, creatinine (CRE), aspartate aminotransferase, alanine aminotransferase, 50 g oral glucose challenge test, fasting blood glucose, fasting insulin, HOMA-IR, and resistin. In contrast, there was a highly statistically significant decrease in the patient group than the control group in haemoglobin (HB). Conclusion In this study, it was found that elevated serum resistin levels could be associated with exaggerated insulin resistance in patients with preeclampsia. Further studies are needed to clarify the role of resistin in the pathophysiology of preeclampsia and insulin resistance.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"446 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"113986595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-05-01DOI: 10.4103/2356-8062.170200
S. Assaad, Mohamed Ghitany, S. Marzouk, M. Lotfy, A. Swidan, H. El-Zawawy
Background Thyroid disorders are the second most common endocrine disorders after type 2 diabetes mellitus. Copeptin, the C-terminal part of pre-pro arginine vasopressin, and brain natriuretic peptide (BNP) are new markers of cardiac and endothelial diseases. The relationship between thyroid status and copeptin has not been studied yet. Serum BNP levels are also affected by thyroid function status; however, its value in the presence of thyroid dysfunction has been recently questioned. Aim of the work The aim of this work was to assess the alteration of serum copeptin and BNP in patients with thyroid dysfunction and the relationship between this alteration and cardiovascular performance in patients with thyroid dysfunction. Materials and methods This study included 60 patients who were divided into two groups: group 1 included 30 patients with hyperthyroidism and group 2 included 30 patients with primary hypothyroidism. A total of 20 healthy euthyroid individuals served as the control group (group 3). All patients and controls were subjected to estimation of serum and urine osmolarity and electrolyte study and evaluation of T3, T4, thyroid-stimulating hormone, serum copeptin, and serum BNP using enzyme-linked immunosorbent assay. Echocardiographic study was conducted to assess left ventricle (LV) systolic and diastolic functions. In addition, endothelial function was assessed by measuring flow-mediated dilatation of the brachial artery. Results In patients with hyperthyroidism, serum copeptin was significantly lower than that in controls (mean = 2.24 ± 1.68 vs. 3.34 ± 2.93 pmol/l, P = 0.03). However, it was significantly higher in hypothyroid patients in comparison with controls (mean = 18.78 ± 11.29 vs. 3.34 ± 2.93 pmol/l, P = 0.0001). Serum BNP in the hypothyroid group was significantly higher than that in the control group (mean = 15.02 ± 6.9 vs. 3.60 ± 1.38 ng/l, P = 0.028). E′/ A′ was significantly lower in hypothyroid patients in comparison with the control group (mean = 1.15 ± 0.72 vs. 1.48 ± 0.48, P = 0.03), and more than half of the patients (53%) had E′/ A′ less than 1, suggesting the presence of diastolic dysfunction in hypothyroid patients. There was a significant negative correlation between ejection fraction (P = 0.002), fractional shortening (P = 0.01), and copeptin in the hypothyroid group. There was a significant positive correlation between copeptin and flow-mediated dilatation (P = 0.01) in the hyperthyroid group. Conclusion Serum copeptin and BNP were significantly increased in hypothyroid patients, whereas serum copeptin was significantly decreased in hyperthyroid patients. In hyperthyroid patients, LV systolic function was increased. More than half of the hypothyroid patients with high serum copeptin levels had impaired LV filling.
背景:甲状腺疾病是仅次于2型糖尿病的第二大常见内分泌疾病。Copeptin是前精氨酸抗利尿素的c端部分,脑利钠肽(BNP)是心脏和内皮疾病的新标志物。甲状腺状态与copeptin之间的关系尚未研究。血清BNP水平也受甲状腺功能状态的影响;然而,其在甲状腺功能障碍患者中的价值近来受到质疑。本研究的目的是评估甲状腺功能障碍患者血清copeptin和BNP的变化及其与心血管功能障碍的关系。材料与方法将60例患者分为两组:1组30例甲状腺功能亢进患者,2组30例原发性甲状腺功能减退患者。20名健康的甲状腺功能正常的个体作为对照组(3组)。所有患者和对照组均采用酶联免疫吸附法测定血清和尿液渗透压和电解质,并评估T3、T4、促甲状腺激素、血清copeptin和血清BNP。超声心动图检查左心室(LV)的收缩和舒张功能。此外,通过测量肱动脉血流介导的扩张来评估内皮功能。结果甲亢患者血清copeptin水平明显低于对照组(平均= 2.24±1.68∶3.34±2.93 pmol/l, P = 0.03)。然而,甲状腺功能减退患者的pmol/l含量明显高于对照组(平均= 18.78±11.29比3.34±2.93 pmol/l, P = 0.0001)。甲状腺功能减退组血清BNP显著高于对照组(平均值= 15.02±6.9 vs. 3.60±1.38 ng/l, P = 0.028)。甲状腺功能减退患者的E′/ A′明显低于对照组(平均= 1.15±0.72比1.48±0.48,P = 0.03),超过一半(53%)的患者E′/ A′小于1,提示甲状腺功能减退患者存在舒张功能障碍。甲减组射血分数(P = 0.002)、缩短分数(P = 0.01)与copeptin呈显著负相关。甲状腺功能亢进组copeptin与血流介导的舒张有显著正相关(P = 0.01)。结论甲状腺功能减退患者血清copeptin和BNP水平明显升高,甲状腺功能亢进患者血清copeptin水平明显降低。甲亢患者左室收缩功能增强。半数以上血清copeptin水平高的甲状腺功能减退患者左室充盈受损。
{"title":"Study of copeptin and brain natriuretic peptide in patients with thyroid dysfunction: relation to cardiovascular performance","authors":"S. Assaad, Mohamed Ghitany, S. Marzouk, M. Lotfy, A. Swidan, H. El-Zawawy","doi":"10.4103/2356-8062.170200","DOIUrl":"https://doi.org/10.4103/2356-8062.170200","url":null,"abstract":"Background Thyroid disorders are the second most common endocrine disorders after type 2 diabetes mellitus. Copeptin, the C-terminal part of pre-pro arginine vasopressin, and brain natriuretic peptide (BNP) are new markers of cardiac and endothelial diseases. The relationship between thyroid status and copeptin has not been studied yet. Serum BNP levels are also affected by thyroid function status; however, its value in the presence of thyroid dysfunction has been recently questioned. Aim of the work The aim of this work was to assess the alteration of serum copeptin and BNP in patients with thyroid dysfunction and the relationship between this alteration and cardiovascular performance in patients with thyroid dysfunction. Materials and methods This study included 60 patients who were divided into two groups: group 1 included 30 patients with hyperthyroidism and group 2 included 30 patients with primary hypothyroidism. A total of 20 healthy euthyroid individuals served as the control group (group 3). All patients and controls were subjected to estimation of serum and urine osmolarity and electrolyte study and evaluation of T3, T4, thyroid-stimulating hormone, serum copeptin, and serum BNP using enzyme-linked immunosorbent assay. Echocardiographic study was conducted to assess left ventricle (LV) systolic and diastolic functions. In addition, endothelial function was assessed by measuring flow-mediated dilatation of the brachial artery. Results In patients with hyperthyroidism, serum copeptin was significantly lower than that in controls (mean = 2.24 ± 1.68 vs. 3.34 ± 2.93 pmol/l, P = 0.03). However, it was significantly higher in hypothyroid patients in comparison with controls (mean = 18.78 ± 11.29 vs. 3.34 ± 2.93 pmol/l, P = 0.0001). Serum BNP in the hypothyroid group was significantly higher than that in the control group (mean = 15.02 ± 6.9 vs. 3.60 ± 1.38 ng/l, P = 0.028). E′/ A′ was significantly lower in hypothyroid patients in comparison with the control group (mean = 1.15 ± 0.72 vs. 1.48 ± 0.48, P = 0.03), and more than half of the patients (53%) had E′/ A′ less than 1, suggesting the presence of diastolic dysfunction in hypothyroid patients. There was a significant negative correlation between ejection fraction (P = 0.002), fractional shortening (P = 0.01), and copeptin in the hypothyroid group. There was a significant positive correlation between copeptin and flow-mediated dilatation (P = 0.01) in the hyperthyroid group. Conclusion Serum copeptin and BNP were significantly increased in hypothyroid patients, whereas serum copeptin was significantly decreased in hyperthyroid patients. In hyperthyroid patients, LV systolic function was increased. More than half of the hypothyroid patients with high serum copeptin levels had impaired LV filling.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"101 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124789625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-05-01DOI: 10.4103/2356-8062.170206
A. Okba, D. Sheha, A. Moustafa, A. Elsherbeny, N. Mohamed, Manar F Aglan
Introduction There is growing evidence that some cases of chronic idiopathic urticaria are associated with various autoimmune diseases such as thyroid autoimmunity. The association between chronic urticaria (CU) and thyroid disorders has been a subject of controversy. Some reports link CU with hyperthyroidism or hypothyroidism. The frequency of thyroid antibodies in patients with chronic idiopathic urticaria reported in 2009 was 30%, which is higher than that previously reported. Objective This is a case-control study that aimed to detect the presence of markers of thyroid autoimmunity (thyroid autoantibodies with or without underlying abnormal thyroid functions) among a cohort of autologous serum skin test (ASST)-positive patients with CU in comparison with ASST-negative CU patients as well as with healthy controls, and correlating it to the severity of urticaria symptoms. Patients and methods This study was carried out on 80 CU patients attending the Allergy and Immunology Clinic of Ain Shams University Hospitals. CU was diagnosed on the basis of the appearance of continuous recurrent hives for more than 6 weeks. The patients were subdivided into the following groups: group A - 40 CU patients with positive ASST; group B - 40 CU patients with negative ASST. In addition, 40 healthy individuals were included in this study as healthy controls. History and general examination were conducted to all study grouos. Assessment of the Urticaria Activity Score-7 and laboratory investigations including those for complete blood count, erythrocyte sedimentation rate, thyroid function, thyroid Abs, namelyantimicrosomal antibody and antithyroglobulin antibody and total immunoglobulin E (IgE), were done. Results Comparison between the three groups showed that antithyroglobulin antibody was highly statistically significant in group A than in both group B and healthy controls. Moreover, antimicrosomal antibody was also found to be of higher statistical significance in group A than in both group B and healthy controls. Although total IgE had no statistical significance between groups A and B, total IgE was found to be statistically significantly higher in group B than in healthy controls. Level of thyroid stimulating hormone was higher in group A than in controls, and free T3 was lower in group A than in group B. Conclusion We suggest that thyroid diseases have a role in CU, which was confirmed by a higher level of thyroid antibodies in the ASST-positive group than in ASST-negative patients and healthy controls.
{"title":"Association between thyroid autoimmunity and chronic urticaria in patients versus healthy controls","authors":"A. Okba, D. Sheha, A. Moustafa, A. Elsherbeny, N. Mohamed, Manar F Aglan","doi":"10.4103/2356-8062.170206","DOIUrl":"https://doi.org/10.4103/2356-8062.170206","url":null,"abstract":"Introduction There is growing evidence that some cases of chronic idiopathic urticaria are associated with various autoimmune diseases such as thyroid autoimmunity. The association between chronic urticaria (CU) and thyroid disorders has been a subject of controversy. Some reports link CU with hyperthyroidism or hypothyroidism. The frequency of thyroid antibodies in patients with chronic idiopathic urticaria reported in 2009 was 30%, which is higher than that previously reported. Objective This is a case-control study that aimed to detect the presence of markers of thyroid autoimmunity (thyroid autoantibodies with or without underlying abnormal thyroid functions) among a cohort of autologous serum skin test (ASST)-positive patients with CU in comparison with ASST-negative CU patients as well as with healthy controls, and correlating it to the severity of urticaria symptoms. Patients and methods This study was carried out on 80 CU patients attending the Allergy and Immunology Clinic of Ain Shams University Hospitals. CU was diagnosed on the basis of the appearance of continuous recurrent hives for more than 6 weeks. The patients were subdivided into the following groups: group A - 40 CU patients with positive ASST; group B - 40 CU patients with negative ASST. In addition, 40 healthy individuals were included in this study as healthy controls. History and general examination were conducted to all study grouos. Assessment of the Urticaria Activity Score-7 and laboratory investigations including those for complete blood count, erythrocyte sedimentation rate, thyroid function, thyroid Abs, namelyantimicrosomal antibody and antithyroglobulin antibody and total immunoglobulin E (IgE), were done. Results Comparison between the three groups showed that antithyroglobulin antibody was highly statistically significant in group A than in both group B and healthy controls. Moreover, antimicrosomal antibody was also found to be of higher statistical significance in group A than in both group B and healthy controls. Although total IgE had no statistical significance between groups A and B, total IgE was found to be statistically significantly higher in group B than in healthy controls. Level of thyroid stimulating hormone was higher in group A than in controls, and free T3 was lower in group A than in group B. Conclusion We suggest that thyroid diseases have a role in CU, which was confirmed by a higher level of thyroid antibodies in the ASST-positive group than in ASST-negative patients and healthy controls.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"21 1-2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132399049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4103/2356-8062.200906
Noha Elsabbagh, Sekina Ahmed, Fouad Eldin Mohammed, N. Kandil, H. Hassan
Background It is well known that aging is associated with several hormonal alterations. However, the consequence of aging on the endocrine function of adipose tissue is not fully elucidated. Adiponectin is a new anti-inflammatory protein secreted exclusively by adipocytes and plays a protective role against insulin resistance and atherosclerosis. Aim of the work The aim of the work was to assess serum adiponectin as a biomarker for atherosclerosis and its relation to the carotid intima–media thickness (CIMT) as a clinical surrogate marker of atherosclerosis in elderly patients. Patients and methods The study was conducted on 80 participants aged 20–85 years who were subdivided into four groups. The first group was the control group (GI), which included 20 healthy young volunteers aged 20–40 years. The other three groups each included 20 elderly participants aged above 65 years who were classified according to arterial blood pressure and serum blood glucose levels into elderly healthy (GII), elderly hypertensives (GIII), and elderly diabetics (GIV). Results The mean adiponectin level (control, 12.48±3.95; GII, 9±3.25; GIII, 8.49±2.40; and GIV, 7.16±3.23) was significantly lower in individuals with high CIMT than in those with low CIMT (GI, 0.64±0.05; GII, 0.75±0.06; GIII, 0.72±0.08; GIV, 1.03±0.15). Adiponectin level was negatively correlated with age, BMI, systolic blood pressure, diastolic blood pressure, triglyceride, low-density lipoprotein cholesterol, and blood glucose, and positively correlated with high-density lipoprotein cholesterol. Conclusion Adiponectin was significantly negatively correlated with CIMT independently of age, sex, and all metabolic risk factors. The present study found that serum adiponectin level in humans is lower in elderly individuals and in patients with diabetes mellitus and essential hypertension than in healthy participants, and is negatively affected by the duration of these diseases.
{"title":"Study of serum adiponectin level as an atherosclerotic index in the elderly and its relationship to carotid intima–media thickness","authors":"Noha Elsabbagh, Sekina Ahmed, Fouad Eldin Mohammed, N. Kandil, H. Hassan","doi":"10.4103/2356-8062.200906","DOIUrl":"https://doi.org/10.4103/2356-8062.200906","url":null,"abstract":"Background It is well known that aging is associated with several hormonal alterations. However, the consequence of aging on the endocrine function of adipose tissue is not fully elucidated. Adiponectin is a new anti-inflammatory protein secreted exclusively by adipocytes and plays a protective role against insulin resistance and atherosclerosis. Aim of the work The aim of the work was to assess serum adiponectin as a biomarker for atherosclerosis and its relation to the carotid intima–media thickness (CIMT) as a clinical surrogate marker of atherosclerosis in elderly patients. Patients and methods The study was conducted on 80 participants aged 20–85 years who were subdivided into four groups. The first group was the control group (GI), which included 20 healthy young volunteers aged 20–40 years. The other three groups each included 20 elderly participants aged above 65 years who were classified according to arterial blood pressure and serum blood glucose levels into elderly healthy (GII), elderly hypertensives (GIII), and elderly diabetics (GIV). Results The mean adiponectin level (control, 12.48±3.95; GII, 9±3.25; GIII, 8.49±2.40; and GIV, 7.16±3.23) was significantly lower in individuals with high CIMT than in those with low CIMT (GI, 0.64±0.05; GII, 0.75±0.06; GIII, 0.72±0.08; GIV, 1.03±0.15). Adiponectin level was negatively correlated with age, BMI, systolic blood pressure, diastolic blood pressure, triglyceride, low-density lipoprotein cholesterol, and blood glucose, and positively correlated with high-density lipoprotein cholesterol. Conclusion Adiponectin was significantly negatively correlated with CIMT independently of age, sex, and all metabolic risk factors. The present study found that serum adiponectin level in humans is lower in elderly individuals and in patients with diabetes mellitus and essential hypertension than in healthy participants, and is negatively affected by the duration of these diseases.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"475 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114750919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}